Business ❯ Pharmaceutical Industry

Novo Nordisk

Drug Development Eli Lilly Financial Performance Market Competition Drug Sales Market Impact Sales Market Performance Drug Pricing Stock Market Product Pricing Market Analysis Market Strategies Product Launch CEO Testimony Drug Prices Manufacturing Constraints Wegovy Semaglutide CEO Statements Drug Production Drug Profits Research and Development Market Dynamics Product Management Market Practices Product Offerings Sales Performance Future Plans Sales Growth Key Drugs Stock Performance Company Strategy Economic Impact Weight Loss Drugs Growth Driver Global Market Expansion CEO Meetings Product Supply Eli Lilly and Co. Product Integrity Employment Obesity Treatments Corporate Executives Corporate Structure Corporate Leadership Drug Manufacturing Market Launch Drug Pricing Agreements Product Liability Pricing Strategies U.S. Market Product Compliance Market Trends Research Partnerships Drug Pricing Strategies Product Development CEO Insights

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

The case seeks to curb Eli Lilly’s consumer ads and could change how head‑to‑head trial results are shown to patients and prescribers.

Novo Nordisk’s Wegovy Pill Shows Strong Results, Reinforcing Stock Rebound

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026

Sam’s Club Joins Costco in Offering $499 Wegovy and Ozempic

Costco Adds $499 Ozempic and Wegovy Offer Across U.S. Pharmacies

Costco to Offer Ozempic and Wegovy for $499 a Month to Self-Pay Members Nationwide

Novo Nordisk Freezes Hiring as Layoffs Loom in GLP-1 Retrenchment

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves